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Introduction
Verification of exposure to cyanide by analysis of biologi-
cal matrices is important in the analysis of both accidental 
exposure and deliberate release of cyanide. It is important 
for forensic applications (i.e. analysis that relates to estab-
lishing evidence and does not affect medical treatment) 
and diagnostic applications (i.e. analysis that establishes 
the presence of a medical condition). There are two major 
approaches used to verify cyanide exposure: (1) direct analy-
sis of cyanide, and (2) analysis of the major cyanide metabo-
lite, thiocyanate. Confirming cyanide exposure through 
direct analysis is difficult due to the consumption of cyanide 
in the daily diet, the volatility of hydrogen cyanide (HCN), 
the nucleophilic properties of cyanide ion (CN−), and the 
rapid metabolism of cyanide (half-life in plasma is reported 
to be from 4 minutes to approximately 1 hour; Hartung 1982; 
Lundquist et al. 1987; Baud et al. 1996; Baskin and Brewer 
1997; Moariya and Hashimoto 2001).
Thiocyanate (SCN−) is the major product of cyanide 
metabolism. The formation of thiocyanate occurs when 
cyanide reacts with a sulfane sulfur donor (Isom and Baskin 
1997), predominantly thiosulfate. This formation is enzy-
matically controlled by rhodanese (thiosulfate sulfurtrans-
ferase; Hebert 1993; Salkowski and Penney 1994 ; Tsuge 
et al. 2000; Baskin et al. 2004). Although it is the major prod-
uct of cyanide metabolism, difficulties have been noted in 
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abstract
ATCA (2-amino-2-thiazoline-4-carboxylic acid) is a promising marker to assess cyanide exposure because of 
several advantages of ATCA analysis over direct determination of cyanide and alternative cyanide biomark-
ers (i.e. stability in biological matrices, consistent recovery, and relatively small endogenous concentrations). 
Concentrations of ATCA in the plasma of smoking and non-smoking human volunteers were analyzed using gas-
chromatography mass-spectrometry to establish the feasibility of using ATCA as a marker for cyanide exposure. 
The levels of ATCA in plasma of smoking volunteers, 17.2 ng/ml, were found to be significantly (p < 0.001) higher 
than that of non-smoking volunteers, 11.8 ng/ml. Comparison of ATCA concentrations of smokers relative to non-
smokers in both urine and plasma yielded relatively similar results. The concentration ratio of ATCA for smokers 
versus non-smokers in plasma and urine was compared to similar literature studies of cyanide and thiocyanate, 
and correlations are discussed. This study supports previous evidence that ATCA can be used to determine past 
cyanide exposure and indicates that further studies should be pursued to validate the use of ATCA as a marker 
of cyanide exposure.
Keywords: 2-amino-2-thiazoline-4-carboxylic acid, ATCA, Biomarker, Cyanide, Gas-chromatography  
mass-spectrometry
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the use of thiocyanate for verification of cyanide exposure. 
Thiocyanate is naturally found in biological fluids, and 
while this is a condition of all cyanide biomarkers, normal 
thiocyanate levels are very high and can be inconsistent 
(Diem and Letner 1970; Pettigrew and Fell 1973; Jarvis 1989; 
Maliszewski and Bass 1955; Yamanaka et al. 1991; Pre and 
Vassey 1992; Tsuge et al. 2000; Hasuike et al. 2004). Large and 
variable background thiocyanate concentrations (i.e. aver-
age SCN− concentrations are approximately 33.1 µM, 60 µM, 
and 590 µM, for blood, urine, and saliva, respectively) make 
it difficult to determine low-level cyanide exposure from this 
metabolite. Ballantyne (1977) also found that concentrations 
of thiocyanate in blood varied unpredictably during storage 
at a number of temperatures and that analytical recovery of 
thiocyanate from whole blood was inconsistent. Large and 
variable concentrations may indicate that thiocyanate is 
involved in a number of biological processes in addition to 
cyanide metabolism. In fact, significant use of thiocyanate 
by biological processes other than cyanide metabolism has 
been established (Wood et al. 1947; Wood and Williams 
1949; Isom and Baskin 1997).
An alternative approach to verification of cyanide 
exposure is to analyze biological matricies for 2-amino-
thiazoline-4-carboxylic acid (ATCA). The formation of 
ATCA from cyanide, as shown in Figure 1, appears to be 
an important biological pathway for cyanide detoxifica-
tion (Salkowski and Penney 1994; Baskin and Brewer 1997; 
Borowitz et al. 2001). When cyanide reacts with cystine, 
ATCA or 2-iminothiazolidine-4-carboxylic acid (ITCA) is 
formed. These two tautomers, ATCA and ITCA, may be in 
equilibrium (Figure 1; Lundquist et al. 1995) and will be 
referred to as only ATCA. Approximately 15% of the initial 
dose of cyanide is converted to ATCA (Wood and Cooley 
1956) by direct interaction of cyanide with cystine and not 
from other processes.
In biological samples, ATCA is stable for months at vari-
ous temperatures (Lundquist et al. 1995; Logue et al. 2005). 
Relatively few techniques have been described to analyze 
ATCA from biological matrices, including spectrophotometry 
(Bradham et al. 1965; Baskin et al. 2006) and high-perform-
ance liquid chromatography (Lundquist et al. 1995). More 
recently, Logue et al. (2005) described a gas-chromatography 
mass-spectroscopic (GC-MS) method to analyze ATCA 
in human urine and reported concentrations of ATCA in 
smokers and non-smokers. Relatively few studies have been 
performed to evaluate the relationship between ATCA and 
cyanide, although recent studies have shed some light on this 
issue. Elevated concentrations of ATCA in the urine of smok-
ers compared to non-smokers have been found (smokers 
inhale a small amount of cyanide while smoking; Lundquist 
et al. 1995; Harris 1996; Logue et al. 2005) and it has been 
established that ATCA is not metabolized further (Wood and 
Cooley 1956; Weuffen et al. 1980; Baskin et al. 2004). ATCA is 
excreted mainly in the urine (Baskin et al. 2004), and its toxi-
cokinetics have not been specifically established. Although 
there are no specific toxicokinetic studies of ATCA, previous 
studies of the behavior of ATCA indicate that it has properties 
consistent with a lasting signature of  cyanide exposure. 
Besides being a marker of cyanide exposure, ATCA may play 
a role in the neurotoxic effects of cyanide, as it appears to 
have some level of neurotoxicity (Bitner et al. 1997).
The relationship between cyanide exposure and markers of 
exposure must be understood in order to utilize a specific cya-
nide biomarker. If a strong relationship is established, foren-
sic, clinical, military, scientific, and veterinary investigators 
could use this marker for diagnostic or forensic confirmation 
of cyanide exposure. The purpose of this study was to further 
evaluate the potential of ATCA for use as a valuable marker 
of cyanide exposure by evaluating the relationship between 
cyanide inhalation and ATCA concentrations in the plasma of 
smokers and non-smokers. These concentrations were com-
pared to similar studies of ATCA, cyanide, and thiocyanate.
Materials and methods
Reagents
ATCA (full chemical name: L-2-amino-2-thiazoline-
4-carboxylic acid) was obtained from Chem-Impex 
International (Wood Dale, IL). A standard stock solution 
(100 g/mL) was prepared in 0.1 M HCl and used through-
out the current study. Oasis solid-phase extraction (SPE) 
columns were obtained from Waters Corporation (Milford, 
MA). The derivatizing agent N-methyl-N-trimethylsilyl-
trifluoroacetamide (MSTFA) was purchased from Pierce 
Chemical Company (Rockford, IL). The internal standard, 
deutereated ATCA (ATCA-d
2
), was obtained from the lab 
of Dr Herbert T. Nagasawa (Department of Veterans Affairs 
Medical Center, Minneapolis, MN), prepared by reaction of 
deuterated L-cysteine (3,3-d
2
) with cyanamide (Nagasawa 
et al. 2004). HPLC grade solvents and reagents were used 
throughout the study and were purchased from Sigma-
Aldrich (St. Louis, MO).
Biological fluids
Plasma samples from human subjects, age 18–60, were 
used to evaluate the applicability of the analytical method. 
Six male subjects (three smokers and three non-smokers) 
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Figure 1. The production of ATCA from cyanide and cystine.
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donated samples of blood at 8:00 a.m. (designated ‘morn-
ing’), at noon, and at 5:00 p.m. (designated ‘afternoon’) on 
three separate days over the course of a week (54 samples 
total). The smoking individuals (as defined by individuals 
who smoke at least five cigarettes per day with no other form 
of tobacco use) represent low level chronic exposure to cya-
nide through cyanide inhalation. Accurate intake of cyanide 
for individuals in this group is difficult to estimate because 
of variation in the number of cigarettes smoked, the cyanide 
dose per cigarette, the act of inhalation, etc. Therefore, these 
individuals will be referred to only as ‘smokers’.
Whole-blood samples were collected (2 mL) and mixed 
with EDTA. The samples were initially vortexed to ensure 
complete mixing prior to separation of the plasma and red 
blood cell fractions by centrifugation. The separate frac-
tions were collected and stored in a freezer until analysis. To 
determine the effect of time variation on plasma concentra-
tions of ATCA, smoking and non-smoking volunteers were 
separated into subgroups which were defined by days of 
week and time of day (e.g. smokers on Friday afternoon). 
Each subgroup was analyzed for significant difference (see 
‘Calibration, quantification, and data analysis’ section). All 
samples were gathered under approved human use proto-
cols from the gathering institution.
Sample preparation
Samples were diluted 1:10 in 1 mL of 0.1 M HCl. Acidifying 
the plasma matrix ensured the amine moiety on ATCA 
(Figure 1) was protonated. Deuterated ATCA (100 L of 
1000 ng/mL ATCA-d
2
) was added to the diluted sample as 
an internal standard. After conditioning with successive 
washes of 1 mL each of methanol and H
2
O, the diluted sam-
ple was aspirated through an SPE column. The column was 
then washed successively with 1 mL each of 0.1 M HCl and 
100% methanol. ATCA was then eluted into 2 mL micro-
centrifuge tubes using 29% (w/w) NH
4
OH. Because highly 
basic solutions can chemically alter the ATCA structure, a 
small amount of concentrated HCl (200 L) was added to 
the centrifuge tube to decrease the solution pH. The solvent 
was removed from the samples in a centrifugal evaporation 
system at 70°C for at least 6 hours. Derivatization of the dried 
samples was carried out at 50°C using 150 L of 30% MSTFA 
in hexane for 1 hour in capped centrifuge tubes to produce 
trimethylsilyl-derivatized ATCA (ATCA-(TMS)
3
).
Gas-chromatography mass-spectrometry
Analysis was performed on an Agilent GC-MS system con-
sisting of a 6890 Series II gas chromatograph, a 5973N series 
mass-selective detector, and a 7683 auto-sampler. The col-
umn used was a DB-5MS bonded phase column (30 m × 0.25 
mm I.D., 0.25 m film thickness; J&W Scientific, Folsom, CA) 
with helium as the carrier gas at a flow rate of 0.1 mL/min. 
The GC oven temperature was initially held at 100°C for 1 
minute, and then elevated at a rate of 15°C/min up to 250°C. 
The gradient was then increased at a rate of 30°C/min up to 
280°C and held constant for 1 minute. The GC was interfaced 
with a mass-selective detector in selected ion monitoring 
(SIM) mode for monitoring abundant ions of ATCA-(TMS)
3
 
(m/z 245, 347, and 362) and ATCA-d
2
 (m/z 349 and 364) with 
a dwell time of 100 ms each. Other parameters are reported 
by Logue et al. (2005).
Calibration, quantification, and data analysis
Calibration samples were prepared in the range of 10–1000 
ng/mL by diluting the stock ATCA solution in water as a 
surrogate and adding 100 ng/mL ATCA-d
2
 as an internal 
standard. Calibration was performed by plotting peak area 
ratios of ATCA to internal standard (ATCA-d
2
) of individual 
ions 362 and 364, respectively. The error involved in analyz-
ing plasma samples for ATCA is reported in standard error of 
the mean throughout the text. Alternatively, it is sometimes 
useful to report the standard deviation of the data. For this 
study, the standard deviation for the analysis of ATCA in 
plasma was 5.2 ng/mL and 4.6 ng/mL for smokers and non-
smokers, respectively. Comparison of the plasma samples for 
significant differences in the ATCA concentrations of smok-
ers compared with non-smokers was accomplished using a 
two-tailed t-test. Comparison of each sub-group of smokers 
and non-smokers (e.g. non-smokers on Friday morning) 
was accomplished by a two-way analysis of variance and the 
Bonferroni multiple range test to identify significant differ-
ences between the identified subsets of volunteers.
Results and discussion
ATCA concentrations in smoker and non-smoker plasma
Human cyanide exposure can be evaluated directly 
through analysis of biological matrices of smokers or 
victims of accidental exposure (Chandra et al. 1980; 
Lundquist et al. 1987; Harris 1996; Their et al. 2000; Tsuge 
et al. 2000; Riddle 2004; Eckstein and Maniscalco 2006; 
Geller et al. 2006; Scherer 2006). Cyanide concentrations 
in the plasma, whole blood, saliva, and tissues of smok-
ers are elevated with respect to non-smokers because a 
small amount of cyanide intake occurs during the act of 
smoking (Chandra et al. 1980; Lundquist et al. 1987; Harris 
1996; Tsuge et al. 2000). There is also an inherent amount 
of cyanide present in blood samples and other biological 
tissue due to the consumption of various foods that con-
tain cyanide and the breakdown of amino acids (Baskin 
and Brewer 1997; Ellenhorn and Barceloux 1997; Jones 
1998). A portion of this inherent cyanide will presumably 
be converted to ATCA (Figure 1; Wood and Cooley 1956; 
Weuffen et al. 1980; Salkowski and Penney 1994; Harris 
1996; Borowitz et al. 2001; Baskin et al. 2004). Therefore, as 
with cyanide and thiocyanate, there should be measurable 
endogenous levels of ATCA in human biological samples. 
In fact, endogenous concentrations of ATCA were found in 
human urine samples, with smokers having elevated con-
centrations relative to non-smokers (Logue et al. 2005). 
Therefore, ATCA concentrations for smokers should also 
be elevated above background levels of ATCA found in 
non-smoker plasma. A representative chromatograph 
for the analysis of ATCA from the plasma of a smoker is 
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presented in Figure 2. As with all cyanide markers, sig-
nificant endogenous concentrations of ATCA dictates 
that ‘normal’ background levels of ATCA for both smokers 
and non-smokers must be known for each individual bio-
logical matrix. Background levels must be known so that 
significantly elevated levels of ATCA, which may indicate 
cyanide exposure, can be determined.
The concentration of ATCA in the plasma of smok-
ing and non-smoking volunteers was evaluated to deter-
mine whether there was a significant increase in ATCA 
concentrations of smokers relative to non-smokers and to 
estimate background levels of ATCA in the plasma of smok-
ers and non-smokers. The plasma concentration of ATCA 
in the volunteers was 17.2 ± 1.0 ng/mL and 11.8 ± 0.88 ng/
mL for smokers and non-smokers, respectively (Figure 3). 
Comparing these two averages with a two-tailed t-test indi-
cates that a significant difference exists between these two 
groups at a 99.9% (p < 0.001) confidence level.
Evaluation of time dependence of ATCA exposure
Plasma samples were gathered throughout each day and over 
the course of a 1-week period. Overall, the ATCA concentra-
tion ranged from 7.03–14.6 ng/mL for non-smokers and 
13.6–19.4 ng/mL for smokers throughout the various times 
during the week (Table 1). Each sub-group (e.g. non-smokers 
at Wednesday noon) was analyzed for significant difference. 
Although the amount of cyanide intake for smokers and 
non-smokers can vary throughout the day and the week, the 
concentration of ATCA did not significantly change (ANOVA 
analysis p-values ranged from 0.84–0.35; the Bonferroni test 
also confirmed that there were no significant differences 
between these groups). The lack of significant variation of 
ATCA concentrations between the day of the week and the 
time of day indicates that the ATCA concentrations are fairly 
stable over time. This would not be expected if the distribu-
tion and depuration half-lives were short (i.e. 1–2 hours); the 
ATCA concentration would increase throughout the day. If 
the distribution and depuration half-life of ATCA are long 
(i.e. multiple hours), fairly stable concentrations of ATCA 
would be seen.
The concentrations of ATCA for each sub-group in Table 1 
are consistently larger for smokers than for non-smokers. 
Although all ATCA concentrations are larger for smokers, the 
difference between smokers and non-smokers on Wednesday 
morning is insignificant. This is most likely due to the limited 
number of samples gathered for each sub-group (n = 3) and 
the error involved in analyzing human plasma samples for 
ATCA. This sub-group illustrates that, although tentative 
conclusions can be made from these sub-groups, a more 
extensive study should be completed to validate the data.
Comparison of ATCA concentrations in human biological 
matrices
Direct comparison of urine and plasma is not possible, but 
ATCA concentrations for smokers in both urine (Logue et al. 
2005) and plasma (this study) matrices are significantly 
higher relative to non-smokers (saliva concentrations of 
ATCA have thus far not been analyzed for smokers and non-
smokers). ATCA concentrations in urine were 115 ± 13 ng/
Table 1. ATCA concentrations in the plasma of smokers and non-smokers during various times during a 1-week period. The error for each entry is 
reported in standard error of the mean (n = 3 for each group).
 Monday Wednesday Friday
 Smokers (ng/mL) Non-smokers (ng/mL) Smokers (ng/mL) Non-smokers (ng/mL) Smokers (ng/mL) Non-smokers (ng/mL)
Morning 19.2 ± 0.9 12.5 ± 4.0 14.7 ± 3.5 14.6 ± 1.3 18.7 ± 2.4 14.2 ± 2.0
Noon 13.6 ± 3.1 7.03 ± 1.6 15.3 ± 2.9 13.1 ± 2.2 18.7 ± 2.3 11.7 ± 1.4
Afternoon 18.1 ± 2.4 11.0 ± 3.5 19.4 ± 6.7 9.96 ± 2.6 16.7 ± 2.4 12.4 ± 4.4
Figure 3. ATCA concentrations in the plasma of smokers compared to 
non-smokers (error bars indicate the standard error of the mean for each 
group). The concentration of ATCA was found to be significantly elevated 
in the plasma of smokers (p < 0.001).
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3
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mL and 87 ± 12 ng/mL for male smokers and non-smokers, 
respectively (standard error of the mean given; Logue et al. 
(2005) reported standard deviations of 46 and 36 ng/mL for 
male smokers and non-smokers, respectively) while plasma 
concentrations were 17.2 ± 1.0 ng/mL and 11.8 ± 0.88 ng/mL 
for smokers and non-smokers.
While comparison of absolute concentrations of cyanide 
biomarkers in different biological matrices is not possible, 
comparison of the ratio of smokers relative to non-smokers 
is possible (e.g. SCN− concentration in smokers’ plasma/
SCN− concentration in non-smokers’ plasma). The ratios of 
mean ATCA concentrations of smoker to non-smoker were 
analyzed from both urine and plasma matrices (Logue 
et al. 2005; current study; Figure 4). These ratios were also 
compared to cyanide and thiocyanate ratios from similar 
studies (Maliszewski and Bass 1955; Lundquist et al. 1985, 
1987; Jarvis 1989; Sano et al. 1989; Yamanaka et al. 1991; 
Pre and Vassey 1992; Tsuge et al. 2000; Hasuike et al. 2004) 
in a number of matrices (blood/plasma, saliva, and urine; 
presented in Figure 4). The ratios are strikingly similar for 
ATCA between plasma and urine with a calculated ratio 
of 1.51 and 1.32, respectively. The ATCA ratio is also simi-
lar to the cyanide ratio, which ranged from 1.44–2.56 for 
other similar studies (Lundquist et al. 1985, 1987; Sano 
et al. 1989; Tsuge et al. 2000; Hasuike et al. 2004). The simi-
larity of the ratios between cyanide and ATCA provides 
evidence that ATCA production may be exclusively, or at 
least predominantly, from cyanide metabolism, and that 
there may be a direct link between elevated ATCA concen-
trations and cyanide exposure. Although cyanide ratios 
show some inconsistency (Figure 4), the range of these 
ratios is relatively small considering the difficulties in cya-
nide analysis and that  different analytical methods were 
used to analyze cyanide in these studies. As opposed to 
ATCA and cyanide ratios, the ratios of thiocyanate are very 
inconsistent between studies (Maliszewski and Bass 1955; 
Jarvis 1989; Yamanaka et al. 1991; Pre and Vassey 1992; 
Tsuge et al. 2000; Hasuike et al. 2004) and even within the 
same study for different biological matrices (Jarvis 1989; 
Yamanaka et al. 1991). The thiocyanate ratio ranged from 
1.56–6.74. The ratio of thiocyanate for most of the studies in 
Figure 4 is larger than the ratio of ATCA or cyanide, which 
is an advantage for analyzing thiocyanate. The inconsist-
ency of the thiocyanate ratio may indicate that production 
or depletion of thiocyanate by sources other than cyanide 
metabolism may be occurring. The variability of the thio-
cyanate ratio may also be caused by fast kinetics of thiocy-
anate production and depletion, where biological matri-
ces gathered at different times may have quite different 
thiocyanate concentrations depending on the biological 
process most relevant. Another explanation as to the vari-
ability of thiocyanate between biological matrices is the 
highly variable tissue distribution of rhodanese (Himwich 
and Saunders 1948; Baskin et al. 2004).
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Figure 4. The concentration ratio (smokers/non-smokers) of cyanide biomarkers (cyanide itself, SCN−, and ATCA) in the urine, blood, or saliva of 
human smokers and non-smokers. Similar studies were differentiated by the biological matrix (blood, urine, saliva) and the analyte studied (ATCA, 
cyanide or thiocyanate), as indicated in the figure. The number below each bar indicates the reference from which the ratio was calculated: CS indi-
cates ‘current study’; 1. Logue et al. (2005); 2. Sano et al. (1989); 3. Lundquist et al. (1987); 4. Tsuge et al. (2000); 5. Lundquist et al. (1985); 6. Hasuike 
et al. (2004); 7. Jarvis (1989); 8. Maliszewski and Bass (1955); 9. Pre and Vassey (1992); 10. Yamanaka et al. (1991). The ratios of cyanide biomarkers were 
1.32–1.51 for ATCA, 1.44–2.56 for cyanide, and 1.56–6.74 for thiocyanate.
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Figure 4 indicates that thiocyanate may not be a good 
marker of cyanide exposure because of highly variable 
endogenous concentrations. Scherer (2006) has also sug-
gested that thiocyanate is limited as a marker of cyanide 
exposure. Comparing the ratios of ATCA and thiocyanate to 
cyanide indicates that ATCA may be a better-suited marker 
for determining cyanide exposure. It should be noted that 
some similar studies were excluded from Figure 4 because 
the high variability in the data was such that the difference 
between smokers and non-smokers of the species analyzed 
was insignificant. Consideration of excluded studies still 
supported the conclusions reached from this treatment of 
the data.
These results, along with previous studies evaluating 
ATCA as a possible marker of cyanide exposure, continue to 
provide evidence that ATCA can be utilized as a marker for 
cyanide poisoning in forensic and possibly diagnostic appli-
cations. The current study may be useful in identifying non-
smoking individuals who may be chronically overexposed to 
cyanide in occupations where cyanide is extensively utilized 
(e.g. gold mining operations). Future work must evaluate 
the behavior (i.e. formation, distribution, and excretion) of 
ATCA during and after controlled cyanide exposures. A rela-
tionship should also be established between the dose of cya-
nide and the formation of ATCA. Overall, this study further 
supports the use of ATCA as a marker of cyanide poisoning.
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